Revised SPC: Zessly (infliximab) 100 mg powder for concentrate for solution for infusion

SPC revised to include Kaposi’s sarcoma (a rare cancer related to infection with human herpes virus 8), which most commonly appears as purple lesions on the skin, as an adverse effect of treatment of unknown frequency.

Source:

electronic Medicines compendium